Choosing the Right Investigator – Difficult but Crucial to Success

Choosing the Right Investigator – Difficult but Crucial to Success

The way clinical trial site feasibility is conducted has changed over the years. Now, choosing the right investigators (site feasibility) for your clinical trial is arguably the most critical decision to ensure enrollment success.  Although overwhelming, what can make it truly daunting is a lack of data. According to Tufts, nearly 50% of investigators fail to meet their enrollment targets and 11% of investigators fail to enroll a single patient.  Even more alarming is the number of investigators available for participation — how does one choose the right investigators (site feasibility) given there are somewhere between 250,000 to 500,000 investigators globally?

Site Feasibility – Why So Crucial for Any Business

Study feasibility examines the practicability of a proposal, business venture or idea. It also provides reasons not to pursue the said project or proposal. When it comes to the operational aspect, the analysis determines whether the plan has the necessary resources for it to be practicable. Therefore, choosing the right investigators (site feasibility) has become so crucial for any business.  Over time, investigator relationship management (IRM) and site relationship management (SRM) is critical to a company’s financial success.

Take a typical Phase III trial with the following criteria:

  • 200 sites in one Phase III trial
  • 22 sites fail to enroll a patient
  • (22 sites) x ($25K to activate site) = $550K

The initial outlay to activate sites (and $550K is a conservative number) is just the start.  It does not even consider other costs, such as adding more sites, time spent with the site, advertising to overcome low enrolling sites, etc. And this is only for one trial.

Also, consider the broader, long-term perspective. You need to consider costs for every day a drug is delayed.  It’s widely accepted a pharmaceutical company loses $1M in revenue for each day lost.

Statistics and pie charts showing short-term and long-term impacts of drug delays. 80% of clinical trials miss their timelines. 48% of doctors fail to meet enrollment targets. 11% of doctors fail to enroll one patient.

Why is it so Difficult?

Challenges of conducting study feasibility

Let’s face it; clinical trial enrollment is not a simple process.  Patients can be difficult to find, and site feasibility is just one of the many aspects that need to be considered.  Companies also need an efficient method to conduct therapeutic area or program feasibility, as well as protocol feasibility.  The Feasibility Focus Matrix below describes each type of clinical trial feasibility.

Feasibility Focus Matrix

As you can see from the graphic above, the key is data analytics.  Without investigator data or an investigator database with a complete picture of feasibility data, it becomes just a guessing game. You will run into the same challenges over and over. Sites are chosen:

  • Despite poor performance (or lack of data to understand their performance)
  • Based on relationships with the CRO or pharma company
  • Because they are viewed as a key opinion leader
  • Based on an incomplete or non-existent feasibility process

Pharma companies need to find a way to utilize industry data:

  • To understand the complete picture of potential investigators
  • To understand if sites are participating in similar trials that might cause enrollment competition
  • To evaluate sites based on protocol inclusion/exclusion criteria

A Data Driven Feasibility Approach

For domestic and global studies, both large and small, a careful, data driven evaluation and selection of investigative sites is crucial for the successful completion of a trial on time, within budget, and with high quality data.

The clinical trial site selection process needs to consider several data-driven factors.

Chart shoing how to evolve the site selection process

For site feasibility, these data-driven factors shown above should consider the investigator experience in four main steps:

  • Finding the right investigators
  • Engaging the right investigators
  • Selecting the right investigators
  • Efficiently Managing relationships with the right investigators

What’s the best clinical trial feasibility tool for Your Organization?

As we move toward the future, pharmaceutical companies continue to need a robust clinical trial feasibility tool and a platform for investigator relationship management (IRM) and site relationship management (SRM). There are clinical trial feasibility tools out there that do evolve with ever-changing business needs. Companies need to make sure they are finding the one that works best for them.

We invite you to discuss with our team of feasibility experts before clinical study feasibility to find out how Intrinsic Clinical Systems can help you avoid costly mistakes and map out a strategy for success.